These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19747832)

  • 1. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
    Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
    Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
    Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
    J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
    Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
    J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
    J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors; synthesis and activity of arecoline oxide tripeptide derivatives.
    Marastoni M; McDonald J; Baldisserotto A; Canella A; De Risi C; Pollini GP; Tomatis R
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1965-8. PubMed ID: 15050638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T; Abe H; Momose I; Takahashi Y; Ikeda D; Akamatsu Y
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5839-42. PubMed ID: 20727746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling, docking studies, and synthesis of novel dipeptide proteasome inhibitors containing boron atoms.
    Lei M; Zhao X; Wang Z; Zhu Y
    J Chem Inf Model; 2009 Sep; 49(9):2092-100. PubMed ID: 19691298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of new vinyl ester pseudotripeptide proteasome inhibitors.
    Marastoni M; Baldisserotto A; Trapella C; Gavioli R; Tomatis R
    Eur J Med Chem; 2006 Aug; 41(8):978-84. PubMed ID: 16713026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
    Mou K; Xu B; Ma C; Yang X; Zou X; Lü Y; Xu P
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2198-202. PubMed ID: 18280155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
    Purandare AV; Wan H; Laing N; Benbatoul K; Vaccaro W; Poss MA
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4701-4. PubMed ID: 15324891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors for cancer therapy.
    Iqbal M; Messina McLaughlin PA; Dunn D; Mallya S; Husten J; Ator MA; Chatterjee S
    Bioorg Med Chem; 2012 Apr; 20(7):2362-8. PubMed ID: 22377673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
    Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
    J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
    Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
    J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
    McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
    Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
    Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
    Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.